KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Shares Purchased by Emerald Mutual Fund Advisers Trust

Emerald Mutual Fund Advisers Trust boosted its stake in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 10.6% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 608,213 shares of the specialty pharmaceutical company's stock after buying an additional 58,525 shares during the quarter. Emerald Mutual Fund Advisers Trust owned 1.22% of KalVista Pharmaceuticals worth $7,019,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in the stock. AlphaQuest LLC boosted its position in KalVista Pharmaceuticals by 17.1% during the fourth quarter. AlphaQuest LLC now owns 17,700 shares of the specialty pharmaceutical company's stock worth $150,000 after purchasing an additional 2,588 shares in the last quarter. Intech Investment Management LLC increased its holdings in KalVista Pharmaceuticals by 58.5% during the 4th quarter. Intech Investment Management LLC now owns 17,204 shares of the specialty pharmaceutical company's stock valued at $146,000 after acquiring an additional 6,349 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of KalVista Pharmaceuticals by 4.9% in the fourth quarter. Vanguard Group Inc. now owns 2,255,243 shares of the specialty pharmaceutical company's stock valued at $19,102,000 after purchasing an additional 104,716 shares in the last quarter. Schroder Investment Management Group grew its position in shares of KalVista Pharmaceuticals by 86.8% in the fourth quarter. Schroder Investment Management Group now owns 805,445 shares of the specialty pharmaceutical company's stock valued at $6,758,000 after purchasing an additional 374,213 shares during the last quarter. Finally, Wellington Management Group LLP increased its stake in shares of KalVista Pharmaceuticals by 4.2% during the 4th quarter. Wellington Management Group LLP now owns 122,863 shares of the specialty pharmaceutical company's stock worth $1,041,000 after purchasing an additional 4,940 shares in the last quarter.

KalVista Pharmaceuticals Trading Down 6.4%

KALV stock opened at $14.52 on Friday. The stock has a 50-day moving average price of $12.57 and a two-hundred day moving average price of $11.23. The company has a market cap of $721.93 million, a PE ratio of -3.93 and a beta of -0.04. KalVista Pharmaceuticals, Inc. has a 12-month low of $7.30 and a 12-month high of $16.32.

KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) last released its quarterly earnings data on Thursday, July 10th. The specialty pharmaceutical company reported ($3.69) EPS for the quarter, missing the consensus estimate of ($0.83) by ($2.86). During the same quarter in the prior year, the firm earned ($1.07) earnings per share. Equities analysts forecast that KalVista Pharmaceuticals, Inc. will post -3.56 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on KALV shares. Jones Trading reiterated a "buy" rating and set a $30.00 target price on shares of KalVista Pharmaceuticals in a report on Wednesday, March 26th. HC Wainwright increased their price objective on KalVista Pharmaceuticals from $20.00 to $27.00 and gave the company a "buy" rating in a research note on Tuesday. Leerink Partners lifted their price objective on KalVista Pharmaceuticals from $18.00 to $20.00 and gave the stock an "outperform" rating in a research report on Monday, July 7th. JMP Securities upped their target price on shares of KalVista Pharmaceuticals from $19.00 to $27.00 and gave the company a "market outperform" rating in a report on Tuesday. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $28.00 price target on shares of KalVista Pharmaceuticals in a research note on Tuesday, April 8th. Eight research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $26.29.

Insider Buying and Selling

In other news, CEO Benjamin L. Palleiko sold 32,979 shares of the company's stock in a transaction on Wednesday, July 9th. The shares were sold at an average price of $15.69, for a total value of $517,440.51. Following the completion of the transaction, the chief executive officer directly owned 369,595 shares in the company, valued at approximately $5,798,945.55. This represents a 8.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Paul K. Audhya sold 2,776 shares of the business's stock in a transaction dated Monday, May 19th. The stock was sold at an average price of $11.84, for a total value of $32,867.84. Following the completion of the transaction, the insider owned 106,611 shares in the company, valued at approximately $1,262,274.24. This trade represents a 2.54% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 48,878 shares of company stock valued at $723,617. 10.50% of the stock is owned by company insiders.

KalVista Pharmaceuticals Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.